Bioinformatics analyses suggest that EPHX2 may participate in metabolic and tumor progression-related regulatory networks and may serve as a prognostic biomarker in LUAD.
Abstract
Background/Objectives: Epoxide hydrolase 2 (EPHX2), which encodes soluble epoxide hydrolase (sEH), is involved in arachidonic acid metabolism and has been associated with inflammation, lipid metabolism, and tumor biology. However, its prognostic significance and biological associations in lung adenocarcinoma (LUAD) remain unclear. This study aimed to investigate the expression profile, prognostic value, and molecular pathways of EPHX2 in LUAD using bioinformatics analyses. Methods: EPHX2 expression was evaluated using TNMplot, GEPIA2, and GEO datasets, while protein expression was assessed using the Human Protein Atlas and CPTAC/UALCAN platforms. Prognostic analyses were performed using Kaplan–Meier Plotter, GEPIA2, and Human Protein Atlas datasets. Co-expression and gene set enrichment analyses were conducted using LinkedOmics, and functional enrichment analyses were performed using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Reactome databases. Correlation and protein–protein interaction (PPI) analyses were evaluated using GEPIA2 and STRING. Results: EPHX2 expression was significantly reduced in LUAD tissues compared with normal lung tissues across datasets, and these findings were supported at the protein level. High EPHX2 expression was associated with better overall survival and retained independent prognostic significance in multivariate Cox analysis. Functional enrichment analyses demonstrated associations with lipid metabolism, arachidonic acid metabolism, cytochrome P450-related pathways, and oxidative processes. Correlation analyses suggested potential associations between EPHX2 and angiogenesis, extracellular matrix remodeling, and hypoxia-related pathways. Conclusions: Bioinformatics analyses suggest that EPHX2 may participate in metabolic and tumor progression-related regulatory networks and may serve as a prognostic biomarker in LUAD.
PPAP2C exhibits the most significant overexpression pattern across 33 cancer types and was significantly associated with advanced clinical stages and aggressive subtypes (HER2+ and TNBC).
Xiao-Xi Lin, Li-Hang Cen, Si-Hui Yue et al.· Frontiers in Pharmacology· 0 citations
The results indicate that METTL9 may contribute to LUAD progression and EMT, potentially in relation to the TGF-β/Smad signaling pathway, potentially in relation to the TGF-β/Smad signaling pathway.
Chen Gong, Yu-Yan Chen, Yuchen Xie et al.· Frontiers in Bioscience· 0 citations
Three EphrinB2/EphB4 signaling pathway and angiogenesis-related biomarkers (PTX3, DLL4, and CITED4) linked with CAD provide new references for the treatment of CAD.
Chunyu Liu, Weiwei Cheng, Xing Wei et al.· Journal of Cardiothoracic Su...· 0 citations
The proposed glutathione metabolism-related signature demonstrated prognostic value in both training and validation cohorts and was associated with immune characteristics, pathway enrichment patterns, genomic alterations, and tumor mutation burden in LUAD.
Z. Sheng, Si-Yu Chen, Su Chen· Cancer Informatics· 0 citations
The risk model and nomogram aided prognosis prediction, providing new insights for CESC treatment and VAC14 and INPP5K were PPM-related prognostic genes for CESC.
H. Meng, Li Tan, Ying Chen et al.· BMC Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.